About Hanmi

한미약품은 창조와 도전을 기치로 신약개발에 매진하는 R&D중심 제약기업입니다.



  • DecPreclinical trial results of “HM95573 (pan-RAF inhibitor)” were presented at Europe Cancer Symposium
  • Hanmi and Ajou University entered into a new anticancer drug development partnership for the development of a novel stem cell therapy
  • Hanmi launched Korea’s first urological combination drug for prostatic hypertrophy and erectile dysfunction “Gugutams”
  • NovPhase 3 results of “Rovelito” were published in the international science journal
  • SepPhase 3 clinical trial results of tamsulosin-tadalafil combined treatment “Gugutams” won the best subject award at the International Society for Sexual Medicine (ISSM)
  • Hanmi signed an exclusive license agreement with Genentech for a Novel Oral RAF inhibitor
  • AugPhase 3 results of “Rosuzet” were published in the international science journal
  • JulHanmi Pharmaceutical Group to establish venture capital firm ‘Hanmi Ventures’
  • Hanmi presented the research results of long acting diabetes-obesity medicines at 2016 ADA
  • Hanmi Science acquires medication management automation company JVM
  • JunHanmi presented the clinical trial results of two targeted anti-ancer drugs at 2016 ASCO
  • AprHanmi wins presidential citation for playing model role in promoting compliance program
  • Hanmi Science purchases land in Yantai Economic & Technological Development Zone in China
  • MarSpectrum Pharmaceuticals Initiates Phase 2 Breast Cancer Trial for Poziotinib, a Novel Pan-HER Inhibitor
  • Hanmi launches Prostatic Hyperplasia medication ‘Hanmi Tams 0.4mg’
  • Hanmi launches antiviral medication ‘Hanmi Flu’
  • FebHanmis’sales reach record high of KRW 1.3175 trillion
  • Hanmi attends JP Morgan Healthcare Conference, presenting new R&D projects
  • JanHanmi founder and chairman, Lim Sung-ki to give away shares worth KRW 110 bil. to employees